ZA200509379B - Memantine oral dosage forms - Google Patents
Memantine oral dosage formsInfo
- Publication number
- ZA200509379B ZA200509379B ZA200509379A ZA200509379A ZA200509379B ZA 200509379 B ZA200509379 B ZA 200509379B ZA 200509379 A ZA200509379 A ZA 200509379A ZA 200509379 A ZA200509379 A ZA 200509379A ZA 200509379 B ZA200509379 B ZA 200509379B
- Authority
- ZA
- South Africa
- Prior art keywords
- dosage forms
- oral dosage
- memantine oral
- memantine
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47897903P | 2003-06-16 | 2003-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200509379B true ZA200509379B (en) | 2006-11-29 |
Family
ID=33539133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200509379A ZA200509379B (en) | 2003-06-16 | 2005-11-17 | Memantine oral dosage forms |
Country Status (16)
Country | Link |
---|---|
US (2) | US20040254251A1 (xx) |
EP (1) | EP1631273A1 (xx) |
JP (1) | JP2006527774A (xx) |
KR (1) | KR20060033727A (xx) |
CN (1) | CN1805737A (xx) |
AU (1) | AU2004249151A1 (xx) |
BR (1) | BRPI0411451A (xx) |
CA (1) | CA2529535A1 (xx) |
IL (1) | IL172233A0 (xx) |
MX (1) | MXPA05012810A (xx) |
NO (1) | NO20055880L (xx) |
PL (1) | PL378902A1 (xx) |
RU (1) | RU2006101225A (xx) |
TW (1) | TW200524639A (xx) |
WO (1) | WO2004112768A1 (xx) |
ZA (1) | ZA200509379B (xx) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7086532B2 (en) * | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
FR2855344A1 (fr) * | 2003-05-22 | 2004-11-26 | France Telecom | Systeme de gestion de contexte pour un reseau comportant un ensemble heterogene de terminaux |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
EP1765287A2 (en) * | 2004-06-17 | 2007-03-28 | Merz Pharma GmbH & Co. KGaA | Immediate release formulations of memantine oral dosage forms |
EP1827385B1 (en) * | 2004-11-23 | 2013-03-27 | Adamas Pharmaceuticals, Inc. | Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
WO2006121560A2 (en) | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
NZ562120A (en) * | 2005-04-28 | 2010-07-30 | Eisai R&D Man Co Ltd | Composition comprising donepezil and memantine as antidementia agents |
US7674793B2 (en) * | 2006-02-10 | 2010-03-09 | Janssen Pharmaceutica Nv | Tricyclic dihydropyrazines as potassium channel openers |
EP2017289A4 (en) * | 2006-04-20 | 2011-07-27 | Itoham Foods Inc | PHARMACEUTICAL COMPOSITION FOR CONFORMATIONAL DISEASE |
US20080008752A1 (en) * | 2006-07-05 | 2008-01-10 | Julia Hrakovsky | Pharmaceutical compositions of memantine |
EP1908748A1 (en) * | 2006-10-05 | 2008-04-09 | Krka | Process for the preparation of memantine and its hydrochloric acid salt form |
MX2009004516A (es) * | 2006-10-27 | 2009-08-12 | Medivation Neurology Inc | Metodos y terapias de combinacion para tratar enfermedad de alzheimer. |
US20080182908A1 (en) * | 2007-01-25 | 2008-07-31 | Vinita Umashankar Vyas | Pharmaceutical compositions comprising memantine |
US20100292341A1 (en) * | 2007-06-29 | 2010-11-18 | Orchid Chemicals & Pharmaceuticals Limited | Quick dissolve compositions of memantine hydrochloride |
EP2583669A1 (en) | 2007-10-10 | 2013-04-24 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
WO2009091932A2 (en) * | 2008-01-18 | 2009-07-23 | Adamas Pharmaceuticals, Inc. | Treatment of mild dementia of the alzheimer's disease type |
US20090247644A1 (en) * | 2008-03-28 | 2009-10-01 | Forest Laboratories Holdings Limited | Memantine formulations |
BR112012013487A2 (pt) | 2009-12-02 | 2017-10-03 | Adamas Pharmaceuticals Inc | Composições de amantadina e métodos de uso |
ES2694224T3 (es) * | 2012-04-24 | 2018-12-19 | Daiichi Sankyo Company, Limited | Comprimido de desintegración oral y procedimiento para producir el mismo |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
KR20190076711A (ko) | 2017-12-22 | 2019-07-02 | 한미약품 주식회사 | 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US6057373A (en) * | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
US6849271B2 (en) * | 2001-04-27 | 2005-02-01 | Verion, Inc. | Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods |
-
2004
- 2004-06-10 CA CA002529535A patent/CA2529535A1/en not_active Abandoned
- 2004-06-10 KR KR1020057024218A patent/KR20060033727A/ko not_active Application Discontinuation
- 2004-06-10 CN CNA2004800167729A patent/CN1805737A/zh active Pending
- 2004-06-10 MX MXPA05012810A patent/MXPA05012810A/es not_active Application Discontinuation
- 2004-06-10 EP EP04754939A patent/EP1631273A1/en not_active Withdrawn
- 2004-06-10 WO PCT/US2004/018506 patent/WO2004112768A1/en active Application Filing
- 2004-06-10 BR BRPI0411451-5A patent/BRPI0411451A/pt not_active IP Right Cessation
- 2004-06-10 PL PL378902A patent/PL378902A1/pl not_active Application Discontinuation
- 2004-06-10 JP JP2006517215A patent/JP2006527774A/ja active Pending
- 2004-06-10 RU RU2006101225/15A patent/RU2006101225A/ru not_active Application Discontinuation
- 2004-06-10 AU AU2004249151A patent/AU2004249151A1/en not_active Abandoned
- 2004-06-15 US US10/869,169 patent/US20040254251A1/en not_active Abandoned
- 2004-06-16 TW TW093117335A patent/TW200524639A/zh unknown
-
2005
- 2005-11-17 ZA ZA200509379A patent/ZA200509379B/xx unknown
- 2005-11-28 IL IL172233A patent/IL172233A0/en unknown
- 2005-12-12 NO NO20055880A patent/NO20055880L/no not_active Application Discontinuation
-
2006
- 2006-07-13 US US11/457,182 patent/US20060251717A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2529535A1 (en) | 2004-12-29 |
WO2004112768A1 (en) | 2004-12-29 |
JP2006527774A (ja) | 2006-12-07 |
US20040254251A1 (en) | 2004-12-16 |
AU2004249151A1 (en) | 2004-12-29 |
EP1631273A1 (en) | 2006-03-08 |
MXPA05012810A (es) | 2006-02-13 |
RU2006101225A (ru) | 2006-06-10 |
BRPI0411451A (pt) | 2006-07-18 |
TW200524639A (en) | 2005-08-01 |
NO20055880L (no) | 2005-12-28 |
IL172233A0 (en) | 2006-04-10 |
PL378902A1 (pl) | 2006-05-29 |
CN1805737A (zh) | 2006-07-19 |
KR20060033727A (ko) | 2006-04-19 |
US20060251717A1 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200509379B (en) | Memantine oral dosage forms | |
GB0322284D0 (en) | Medicament dispenser | |
AU2003244650A8 (en) | Medicinal compounds | |
GB0204719D0 (en) | Medicinal compounds | |
HK1107768A1 (en) | Solid drug for oral use | |
IL174342A0 (en) | Chronotherapeutic dosage forms | |
GB0324886D0 (en) | Medicinal compounds | |
IL172824A0 (en) | Pharmaceutical formulations | |
EP1553925A4 (en) | ORAL DOSAGE FORM WITH MODIFIED RELEASE | |
GB0302671D0 (en) | Pharmaceutical formulations | |
GB0303396D0 (en) | Medicinal compounds | |
AU2003238670A8 (en) | Fast disintegrating oral dosage forms | |
GB0209668D0 (en) | Oral devices | |
GB0302672D0 (en) | Pharmaceutical formulations | |
GB0328490D0 (en) | Medicinal compounds | |
HK1092715A1 (en) | Melt-formulated, multi-particulate oral dosage form | |
GB0325383D0 (en) | Oral formulations | |
GB0206505D0 (en) | Pharmaceutical combination | |
GB0316341D0 (en) | Pharmaceutical formulations | |
EP1614417A4 (en) | SOLID PREPARATION FOR ORAL USE | |
PL373409A1 (en) | Pharmaceutical combination | |
ZA200600560B (en) | Combined doses | |
GB0315019D0 (en) | Dosage form | |
GB0316335D0 (en) | Pharmaceutical formulations | |
GB0220451D0 (en) | Pharmaceutical use |